Cargando…
SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern
COVID-19 in immunocompromised hosts has emerged as a difficult therapeutic management problem. Immunocompromised hosts mount weak responses to SARS-CoV-2 and manifest infection outcomes ranging from severe disease to persistent infection. Weakened immune systems mean greater viral loads and increase...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society for Clinical Investigation
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014096/ https://www.ncbi.nlm.nih.gov/pubmed/36919696 http://dx.doi.org/10.1172/JCI168603 |